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Introduction
============

In the previous issue of *Critical Care*, Amrein and colleagues \[[@B1]\] report a single-center observational study of 655 surgical and non-surgical critically ill patients over a 2-year period and describe the association between vitamin D status and seasonality and mortality in critical illness. Vitamin D, traditionally considered important for the maintenance of calcium homeostasis and musculoskeletal health, is now widely recognized for its extra-skeletal 'pleiotropic effects'. Over the past decade, data from biochemical and molecular genetic studies indicate that vitamin D - particularly its active form, 1,25-dihydroxy cholecalciferol (1,25-dihydroxy-D3) - has a much wider role. These pleiotropic effects include potentiation of antimicrobial action and cardio-protective and immunomodulatory effects. The discoveries that most tissues and cells in the body have vitamin D receptors and that several possess the 1-α hydroxylase enzyme have provided novel insights into the pleiotropic actions of this vitamin \[[@B2]\].

Hypovitaminosis D: Prevalence and associations with clinical outcome
====================================================================

Vitamin D is synthesized in the skin and then undergoes 25-hydroxylation in the liver to 25-hydroxy-D3 followed by 1α-hydroxylation, especially but not exclusively in the kidneys, to 1,25-dihydroxy-D3. Based on optimal bone health, a widely used definition considers a serum 25-hydroxy-D3 of less than 20 ng/mL (50 nmol/L) to be a vitamin D deficiency, 20 to 30 ng/mL (50 to 75 nmol/L) to be insufficient, and more than 30 ng/mL (75 nmol/L) to be normal. Although renal 1α-hydroxylase activation may be important for circulating 1,25-dihydroxy-D3 levels, locally 1,25-dihydroxy-D3 formed by tissue 1α-hydroxylase is critical in mediating the pleiotropic actions of vitamin D. Vitamin D sufficiency is required for both the endocrine and paracrine arms of the axis to function effectively.

There is increasing evidence that vitamin D deficiency is common in hospitalized patients and particularly in the critically ill. Hypovitaminosis D has been associated with increased incidence of a number of autoimmune conditions and adverse outcomes in cardiac transplant recipients and the general population \[[@B3]\]. Although vitamin D insufficiency does not pose immediate health hazards in otherwise healthy individuals, it may be detrimental during critical illness, as the circulating vitamin D pool functions as an important reservoir for local conversion to the active metabolites at tissue level during stress \[[@B4]\].

Global interest in the significance of vitamin D deficiency in critical illness was triggered in 2009 following a report by Lee and colleagues \[[@B5]\], who noted a previously under-recognized high prevalence of hypovitaminosis D. Only 7 % of patients were vitamin D-sufficient, and a predicted mortality was three times higher in deficient patients. Subsequently, a number of studies in critically ill patients have reported a prevalence ranging from 38 % to 100 %, which is about 50 % higher than that for patients in general medical wards.

Several observational studies in critically ill patients have also demonstrated an association between vitamin D deficiency/insufficiency and poor outcomes. These include increases in illness severity and risk of death, ICU length of stay \[[@B6]-[@B8]\], ventilator requirement \[[@B9]\], rates of infection (including ventilator-associated pneumonia) \[[@B10]\], blood culture positivity \[[@B11]\], organ dysfunction, and short-term and long-term hospital mortality \[[@B5],[@B9],[@B11]\]. Furthermore, ICU and hospital costs were found to be higher for vitamin D-deficient patients.

In this context, the study findings of Amrein and colleagues are in accord with previously published data. Vitamin D levels were categorized by month-specific tertiles (high, intermediate, and low) to reflect seasonal variation of serum 25-hydroxy-D3 levels. There was a high prevalence of vitamin D deficiency and insufficiency. Adjusted hospital mortality was significantly higher in patients in the low and intermediate compared with those in the high tertiles. No sepsis-related fatality was observed in the highest month-specific tertile or in vitamin D sufficiency. The authors concluded that low 25-hydroxy-D3 status is significantly associated with all-cause and sepsis mortality in the critically ill and suggested that interventional studies are warranted to study the effect of vitamin D supplementation on outcome in this population. However, the indications for vitamin D assays in these patients were unclear; it was a convenience sample resulting in a selection bias as only patients who had vitamin D assays performed were chosen. There were no differences in bacteremia between survivors and non-survivors. Data on inflammatory markers were not reported. Moreover, vitamin D levels are influenced by fluid shifts and diurnal variability, throwing into doubt the significance of a single measurement \[[@B12],[@B13]\].

Despite these limitations, the study adds to the burgeoning volume of literature on the prevalence of hypovitaminosis D in critically ill patients and the resulting potential for adverse outcomes. Where do we go from here? There have been calls for universal vitamin D supplementation in critically ill patients. Given the present evidence, this would be premature as a number of caveats still remain.

The criteria for definitions of vitamin D sufficiency are based on bone health; the optimal level for pleiotropy remains unclear. Moreover, little data exist on the bio-active form, 1,25-dihydroxy-D3, in critical illness and association with outcomes. Reports of supra-physiological levels of 1,25-dihydroxy-D3 following inflammatory response in critically ill patients \[[@B12]\] and, more recently, evidence of extra-renal production of 1,25-dihydroxy-D3 \[[@B14]\] have been published. Furthermore, the high degree of protein binding of 25-hydroxy-D3 and consequently the relevance of free levels, particularly in the context of altered pharmacokinetics associated with critical illness, remain to be elucidated.

Conclusions
===========

The observational studies available do not suggest causation, and hypovitaminosis D may be simply a marker of poor health, which predicts patients who would have poorer outcomes. Reports that supra-physiological levels of 25-hydroxy-D3 may be associated with adverse outcomes are also emerging \[[@B15]\]. The only means to clarify the role for supplementation is to conduct appropriate dose-response studies followed by a high-quality placebo-controlled randomized trial of vitamin D supplementation in this vulnerable population. Vitamin D is inexpensive and, if it is shown to be beneficial, there is no barrier to rapid implementation into routine clinical practice worldwide.
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